The government is making a new push into the biotechnology sector by investing in a company that will focus on the development of a drug for treating AIDS.
The state-owned National Development Fund (NDF) will pump in US$20 million to help establish a biotech firm to be called TaiMed Biologics, Council for Economic Planning and Development Chairwoman Ho Mei-yueh (何美玥) told a press conference yesterday.
The move is one of a package of government measures designed to turn the nation's biotech industry into a trillion-dollar sector, following in the footsteps of the foundry and display industries.
PHOTO: CHEN TSE-MING, TAIPEI TIMES
Of the NT$30 billion (US$907 million) budget the government plans to invest in the biotech sector, the state fund has directly invested NT$8 billion in 12 biotech companies, Ho said, adding that the government could pump in more capital to fuel the industry's growth even after the budget is expended.
The new biotech company will be chaired by former vice premier Tsai Ying-wen (
David Ho told the press conference that, although it was impossible to know whether the NDF would see significant returns from its investment in TaiMed Biologics, this kind of investment is needed to stimulate the industry.
TaiMed Biologics purchased the patent for the drug TNX-355, which was developed by US-based Genentech Inc, and plans to complete development of the drug, which blocks HIV from entering human cells, in three years.
After launching TNX-355 on the global market, TaiMed Biologics will devote itself to developing flu and bird flu vaccines, he said.
If TaiMed Biologics later establishes a plant to manufacture drugs or other medical products, the NDF would also finance that, Ho Mei-yueh said.
Inviting private enterprises to jointly invest in TaiMed Biologics, the CEPD chairwoman said she had a shortlist of possible investors and would first approach Terry Gou (郭台銘), chairman of Hon Hai Precision Industry Co (鴻海精密).
On Sept. 4, Gou announced he would donate NT$15 billion to National Taiwan University to fund biomedical engineering projects and the construction of a hospital for treating cancer.
In June, Gou, who leads the world's largest contract maker of electronic components, reportedly said he would donate NT$100 billion to fund cancer research by scientists in Taiwan and China.
"I will brief him [to try to win] his support for the company [TaiMed Biologics]," Ho Mei-yueh said.
To encourage development of the biotechnology and pharmaceutical industry, the legislature in June passed tthe Biotech and New Pharmaceutical Development Statute (
The new law stipulates that 35 percent of company investment in R&D and personnel training in the two sectors is tax-deductible for the next five years.
If a firm's expenditure on R&D and personnel exceeds its average spending in the previous two years, 50 percent of the extra amount is tax-deductible.
In addition, employees in the industries who receive stock options do not need to pay income tax on their shares.
Government researchers who get permission from the institute where they are employed can also cooperate with private companies to develop new drugs, while researchers can work as consultants at private companies.
DEJA VU: Echoing the probe into real-estate giant Evergrande Group, the bank is under Beijing police scrutiny after last week, telling investors it is ‘severely insolvent’ Chinese authorities said they recently opened criminal investigations into Zhongzhi Enterprise Group Co’s (中植企業) money management business, days after the embattled shadow banking giant revealed a shortfall of US$36.4 billion in its balance sheet. Police in Beijing said in a statement on WeChat that they took “criminal mandatory measures” against multiple suspects, identifying one by their last name, Xie (解). They urged investors to report cases or provide leads to the authorities, including filing complaints online. Xie Zhikun (解直錕), the group’s founder, died in 2021, but several of his relatives are executives at the company. The statement did not elaborate on what
CONSIDERATIONS: The NSTC instructed the park to assist laid-off workers and urge companies to use furlough programs to ease the effects of falling demand Firms in the Hsinchu Science Park (新竹科學園區), which houses major tech companies, reported laying off 496 employees last month amid weakened global demand, Hsinchu Science Park Bureau director-general Wayne Wang (王永壯) said yesterday. Wang told a news conference that 48 companies in the science park laid off employees last month, including one hard disk supplier which let go 241 employees as part of a plant closure due to falling demand. Other companies reported sporadic layoffs as they adjusted to weakening demand, he said. Wang made the remarks after local media reported the layoffs over the weekend. Although the global economy is struggling with high
German Chancellor Olaf Scholz and German Minister for Economic Affairs and Climate Action Robert Habeck have promised to solve investment subsidy issues for Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and Intel Corp, despite the country’s budget woes. Uncertainty over the funding to TSMC and Intel has arisen after a ruling by the German Federal Constitutional Court, which cast doubt over subsidies for construction of local semiconductor chip plants. On Nov. 15, the court ruled that the German government’s decision last year to reallocate 60 billion euros (US$65.74 billion) of unused funding from COVID-19 pandemic support measures to its Climate and Transformation Fund
NEW TREAD: The Taiwanese shoe brand paired with TSMC to turn silicon waste into a circular economy good, following its success making shoes from coffee grounds Ccilu International Inc (馳綠國際), a Taiwan-based footwear brand, has become the first company in the world to turn silicon waste from contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) into eco-friendly shoes. Last year, the global footwear industry saw the first pair of pressure-relief slippers made from recycled silicon waste by Ccilu. The brand continued to unveil follow-up collections, including sports shoes and massage slippers made from the same materials. In an interview with CNA, Ccilu CEO Wilson Hsu (許佳鳴) recalled the company’s innovation of the first pair of slippers made from silicon waste after its silicon waste treatment partner, Semisils Applied Materials